We're Creating a Structure With One End in Sight — The End of Cancer.
Since 1947, Dana-Farber has been at the forefront of blending exceptional cancer care with leading-edge, transformative science. At the core of what we do is a patient-centered approach with a singular focus — cancer care. That focus has driven us throughout our history, and it has resulted in plans for a new dedicated inpatient cancer hospital, and a transformative clinical collaboration.
Owned and operated by Dana-Farber, the proposed Future Cancer Hospital will be the only independent cancer hospital in the region. It is the right care model for the future of cancer care and will allow us to provide the best care for our patients for years to come.
Our new collaboration with Beth Israel Deaconess Medical Center (BIDMC), a Harvard-affiliated academic medical center, and its affiliated physician group, Harvard Medical Faculty Physicians (HMFP), will provide cancer patients with integrated cancer care in an environment focused exclusively on cancer.
Combined, the proposed Future Cancer Hospital and the new collaboration will pair our singular focus on cancer and clinical leadership with the world-class expertise of BIDMC and its HMS-affiliated faculty physicians to care for all the cancer and sub-specialty needs of Dana-Farber’s patients and their families.
